First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as
first-line treatment could be considered a promising approach to improve the outcome of BRAF
mutant metastatic colorectal cancer patients